The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 398 participants.
Also called NCT06750783
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 398 participants
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Registry
-
NCT06750783
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06750783. Randomized; no masking; primary purpose treatment. Start 2024-12-31 (actual); primary completion 2026-03-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
- Acronym
- Xuezhikang
- Condition
- Prediabetic State (IGT)
- Intervention (Drug)
- Xuezhikang
- Intervention (Drug)
- Atorvastatin
- Lead sponsor
- Beijing Tsinghua Chang Gung Hospital
Record details
- Record id
cardio:ct-nct06750783- Content hash
f233d17d125da9f75416e0faa71e539ec8399c8d84aa2d51002b7946536b3004